SUMMARY Representatives of 17 bone marrow transplant (BMT) teams met to discuss the problems of infection after BMT. With experience of more than 2200 transplanted patients over the past 10 yr, the changes in the patterns of infection were surprisingly similar.
Infection remains one of the main problems in bone marrow transplantation (BMT) . Patients are at risk of severe exogenous infection for months after a transplant and may also experience reactivation of endogenous infections. In pneumonitis, which is a major hazard especially after total body irradiation (TBI), infection is an important factor in many cases (perhaps in all), while the other main complication of transplantation, graft versus host disease (GvHD), may be precipitated or complicated by infection. Full control of infection, therefore, constitutes a vital step in the perfection of BMT procedures and a step which, theoretically at least, should be attainable.
A workshop on this topic sponsored by the Leukaemia Research Fund was held at the Royal Marsden Hospital on 25 June 1982. The intention of the conference was to bring together experience from many marrow transplant units and to review their incidence and patterns of infection and the methods of preventing or treating infection so as to provide an overview not previously available except by searching out and correlating individual reports from the published work of each centre. The questions addressed were concerned with the comparative incidence and experience of specific infections, with the regimens of decontamination, isolation, recontamination, prophylactic antibiotics, granulocyte transfusions and other measures used to prevent infection. Diagnostic procedures and treatAccepted for publication 6 January 1983 ments were also compared and the general question of the relation of infection and GvHD in mouse and man was particularly emphasised. A summary of the workshop with key references has been compiled.
Methods
A questi)nnaire sent to each centre requested their transplant methodology and the incidence and severity of certain infections. We wished to know the numbers, nature and diagnosis of BMT recipients, the pregraft chemoradiotherapy schedules and details of the protocol used to prevent GvHD. We did not request statistics on survival, leukaemia relapse or the quality of life nor did we ask for descriptive details of GvHD. We wished to know the methods used to prevent infection immediately after BMT and after discharge from hospital; the nature, degree and duration of isolation; the prophylactic antimicrobial agents used and their route, of delivery; the use of prophylactic granulocytes or a protected diet; and how long these measures continued after BMT and what new measures were adopted or instructions given on discharge home. who felt they had particular experience to convey. The Tables (see later) have been constructed from these data and the text contains salient points which arose in discussion.
Results

PREVENTION OF INFECTION:(TableS la and b)
These show the measures currently taken in 17 BMT centres to limit infection after BMT in both inpatients and outpatients. Five centres (three in the UK) do not use filtered air. Two centres (Seattle and Memorial) include a comparison of LAF with simple room isolation (as part of wider trials) and in time might be able to comment on whether stringent isolation still confers additional benefit today. It is unfortunate that both these centres include antibiotics normally regarded as important in treatment as components of their prophylactic antimicrobial regimens. No centre (except perhaps Munich) is comparing minimal isolation with more sophisticated isolation techniques while both groups receive non-absorbable antimicrobial agents.
Watson
It is not possible to compare the efficiency of different antibacterial regimens in this report. One centre, Baltimore, has used no prophylactic oral antibacterial agents (or protected diet) at the time of BMT since June 1981 so their reports of Grampositive infections (Table 5) , Gram-negative infections and perhaps indirectly viral infections are of interest but include data from the time when oral prophylactic antibacterial agents were used. Future reports from Baltimore and from Seattle of their experiences with isolation plus antifungal prophylaxis only should allow an up-to-date assessment of the contribution made by prophylactic antibacterial agents in the prevention of infection and GvHD. Together with their more simple isolation studies the data being generated by these centres could have wide ranging implications for units starting BMT. Nystatin remains the most popular prophylactic antifungal agent although the early data and clinical acceptability of mepartricin make this absorbable methylated relative of amphotericin perhaps worthy of a wider trial than only Genoa. Data from the Royal Free Hospital' suggested that 2/66 patients, without any change in the incidence of these problems in the rest of the hospital. Adequate filtration to exclude the smaller spores ofAspergillus fumigatus was essential in preventing disease.
Two studies of prophylactic ketoconazole versus oral nystatin and amphotericin were reported. Both Prentice' and Gluckman independently described considerable reduction in fungal infections in the patients who received ketoconazole but controls were historical in the Gluckman study and the dose of nystatin (1.2 x 106 units/day) considered inadequate by some in the other. The optimal prophylactic regimen is not yet agreed. Prentice described considerable reduction in the absorption of ketoconazole after day 21 associated with abnormalities of gastrointestinal function. ' Mepartricin, an orally absorbed methyl ester of an amphotericinlike heptane is without renal toxicity as described by Bacigalupo (Genoa)2 and appears of great interest although his incidence of positive candida cultures when using either prophylactic mepartricin or ketoconazole was similar though much less than in the patients who received nystatin or miconazole.
Even adequate treatment may not be sufficient unless also commenced at an early stage. Because it is unusual to culture Aspergillus sp in the absence of invasive disease, it was strongly recommended that any patient with a positive culture for aspergilli should receive a total of 2 g amphotericin B; and if treating possible clinical disease the early institution of treatment is of the greatest importance. A suggested schedule is 1 mg amphotericin test dose intravenously followed one hour later by 20 mg infused over 24 h and then 50 mg during each 24 h to a total of 2 g. Some felt 5-fluorocytosine and rifampicin were helpful, and that radiological sinusitis with a pulmonary infiltrate should be regarded as due to Aspergillus sp until proved otherwise.
Cytomegalovirus infections and pneumonitis (Table   3) Cytomegalovirus (CMV) gave rise to much discussion because of the prevalence of fatal CMV pneumonitis, the difficulty of aetiological diagnosis in pneumonitis, the lack of effective treatment and the suspicion that most CMV infection in seronegative BMT patients is iatrogenic.
Between 10% and 50% of patients develop CMV infection after BMT. Fifty-nine percent of USA patients with CMV developed CMV pneumonitis compared to 23% of European patients, the proportion of such pneumonitis proving fatal being 60% on both sides of the Atlantic. Factors which increase the incidence of CMV pneumonitis and CMV infection include being a caucasian; GvHD grade II or greater; age >12 yr; lung radiation greater than 6
Gy; preceding recipient CMV seropositivity; recipient seronegativity with donor seropositivity (not in Seattle); the giving of granulocytes and degrees of recipient/donor HLA matching which are less than fully compatible.3
Pneumonitis was twice as common after BMT for acute leukaemia as after aplastic anaemia (p < 0.005) but even with transplants for aplasia the incidence varies with the conditioning regimen. Assessed 15 weeks after BMT for aplasia, cyclophosphamide, PAPACY and TBI preconditioning regimens were associated with incidences of pneumonitis of 8%, 30%, and 70% respectively.3 The lesser incidence of interstitial pneumonitis after syngeneic BMT is due mainly to an absence of CMV pneumonitis. True idiopathic pneumonitis seems as common after syngeneic BMT as after allogeneic BMT. Barrett and Depledge4 have shown a clear relation between total lung radiation dose and the incidence of lung complications after BMT It is likely that the early use of acyclovir will reduce this. Discussion of herpes simplex (HSV) mainly centred around the use of acycloguanosine (ACG). Intravenous (250mg/m2 tds)'°and to a lesser extent oral (5mg/kg bd)" prophylaxis were effective in preventing HSV lesions developing and intravenous therapy led to rapid resolution of active lesions. '2 The place of oral therapy is still to be resolved but the problems of rapid recurrence of lesions after treatment is stopped would probably remain. Resistance to ACG by HSV was reported but all strains which have been tested lacked thymidine kinase (3/3 in Seattle, 6/6 in Baltimore and St Louis, Paris) and consequently had thrived despite ACG.'3 Several centres reported recurrent HSV after stopping treatment but almost all patients responded well to a second course. Meyers (Seattle) described a brief syndrome, occurring in six patients, five of whom had received high ACG doses, which was characterised by tremor, disorientation and mood changes but generally without focal signs. Although attributed by Meyers to ACG, Saral and Gluckman had seen this in the absence of ACG and attributed it to a late effect of the preconditioning. Not one of the six encephalitides in Table 4 was proven by biopsy. No-one suggested that strange neurological syndromes may be due to cyclosporin A which has been shown to produce considerably different toxic effects in younger age groups.'4 Concern was expressed by some that ACG might affect bone marrow recovery despite the difficulty of differentiating ACG effects from those of the virus.
No data were presented or cited to implicate ACG in slow marrow recovery. Workers reported that 30 mg/kg/dose of ACG if given with one litre of fluid per gram of drug caused no renal toxicity.
Other viruses
The Baltimore experience with viral gastroenteritis after BMT was recently reported. '5 This showed 40% of BMT recipients became infected with one or more viruses during their initial admission and drew particular attention to adenovirus, rotavirus and Coxsackie virus as pathogens. Seventeen of 31 patients (13 of 22 viral excretors) with enteric pathogens in their stools died compared to 6 of 47 without enteric pathogens.
Other centres reported their commoner isolates. Papovavirus, usually BK strain, was found in the urine of between 30% and 80% of BMT recipients (Memorial, Baltimore, Westminster), with a possible association with mild hepatotoxicity. 16 No definite evidence of neurotoxicity has emerged, even in those who excreted JC virus. Adenovirus caused at least 70 severe infections with a mortality rate of about 15% reported from several centres. Serotypes 2, 5 and 11 predominated and infection was manifest most usually as a respiratory disease which rapidly led to severe gut and renal damage. Coxsackie A 1, 2, 5 have predominantly been shed without disease, although both Coxsackie virusinfected Baltimore patients died. One patient died of influenza in Basel. Epstein-Barr virus remains an area ripe for exploration. Although Westminster reported 14 seroconversions after BMT, there was only a possible association with hepatitis and GvHD.
Infections with Gram-positive cocci (Table 5) Staph aureus infections were not considered a major problem. With the exception of Seattle and Baltimore, there were 45 infections reported of which seven (16%) were fatal. Saral (Baltimore) felt Staph aureus was a major cause of infection in chronic GvHD and Meyers described Staph aureus as a frequent cause of late infection (>100 days after BMT).
In contradistinction, Staph epidermidis infections are currently the most common cause of bacteraemia in Seattle and certain other centres, and although not often fatal (8 of 103 on whom full data were available) protracted illness, extensive soft tissue infections, endocarditis, pneumonia and infected emboli were described. Frequent resistance to all antimicrobials except vancomycin was found in some centres and this antibiotic is included in the combination of antimicrobials used at the onset of pyrexia in Seattle despite concern about the toxicity of the combination of cyclosporin A and vancomycin. Double lumen "Hickman" catheters allowing separate channels for giving and withdrawal did not reduce the incidence of Staph epidermidis septicaemia. However, Westminster reported that careful attention to sterile technique plus keeping the end of the "Hickman" line in a sterile finger cot or the catheter/giving set junction in a sterile plastic bag had eliminated their problem writh Staph epidermidis septicaemia, not now seen for 10 months. '7 There was general agreement that indwelling intravenous lines should be removed in the event of septicaemia with the possible exception of Staph epidermidis.
Pneumococcal infections remain a problem, particularly later than 100 days after BMT. Resistance to Septrin, delayed and poor responses to Pneumovax immunisation (particularly the 6A antigen-the most common serotype in Los Angeles) and impaired splenic function were all cited as reasons, but no-one commented on a change in their local incidence once prophylactic penicillin was given. protected. Similar results were reported by Truitt who used AKR mice with end-stage leukaemia to show that decontamination should commence a minimum of 10 days before BMT in order to have maximum reduction in post-BMT mortality. Maximum benefit was obtained only when both decontamination and isolation in a protective environment were used. Decontamination and isolation per se did not eliminate the GvHD reaction in immunosuppressed leukaemic AKR mice; however, much of the mortality associated with GvHD was eliminated. The degree of GvHD remaining was dependent on the compatibility of the donor and host as well as the dose of post-thymic lymphocytes transplanted. Bacteria-free "leukaemia-cured" AKR chimeras could be returned to a conventional microbial environment without significant increase in mortality but the timing of this reconventionalisation was crucial.
Vossen22 reported data from Leiden concerning high dose total (Neo Co Ceph) and low dose selective (Neo Co) prophylactic oral antimicrobial decontamination and the incidence of acute GvHD in children transplanted for aplasia (Table 6 ). Suppressed stools were those from which Gram-negative bacteria or fungi could not be isolated. Children with suppressed stools had less GvHD (p < 05 > 0-1) but "total" decontamination resulted in a much lower incidence of GvHD though the proportion of consistently suppressed stools was similar. There was no difference in the incidence of infections. Early onset acute GvHD is due to the cytotoxicity of transplanted mature lymphocytes whereas late onset (>3 weeks after BMT) acute GvHD is caused by T lymphocytes which have matured out of the graft under the influences prevailing at that time. Severe early onset GvHD was seen only in children with hereditary forms of aplasia, but exclusion of these five children shows late onset GvHD in 3 of 12 suppressed.
The most striking "effect" on late onset acute GvHD was seen in the totally suppressed group: no GvHD out of five non-hereditary aplasias. The same "effect" was not seen in the selectively suppressed group: three GvHD out of seven nonhereditary aplasias. It was suggested that gut bac- teria or their products together may contribute to GvHD. Stool endotoxin concentrations suggested an association with the development of GvHD but the inclusion of oral colistin, an endotoxin-binding agent, in the regimens made interpretation difficult. The low rate of chronic GvHD (2 of 25 aplastics; 0 of 8 acute leukaemia patients) may reflect the degree of microbial suppression achieved by Vossen et al. 22 Active and passive recontamination were briefly discussed. Various centres recounted anecdotes of acute GvHD developing shortly after either active recontamination, withdrawal of decontamination or discharge home yet while continuing oral Septrin, but no centre has any study of the precipitation of GvHD in relation to the changing stool microbiology after discharge from hospital.
Conclusion
It was evident that very different degrees of importance are attached in different places to the role of infection in causing GvHD. Experimental data would seem to indicate the need for relatively complete and prolonged bacterial decontamination before and after transplant (perhaps as much as 12 days before and 60-80 days after) but the practical difficulties of doing so (which would among other things reduce the number of transplants done) and the difficulties of assessing the benefits have largely inhibited attempts at comparative trials. With an ever-expanding scope for marrow-transplants-for example, for thalassaemia and for the use of nonmatched donors-this problem will remain without easy solution. The workshop was an invaluable opportunity to compare detailed results and the information exchanged will undoubtedly lead to improved practices in many circumstances, but no obvious pathway to clarify the relation of infection and GvHD in man was proposed.
